We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App





AI-Powered Lyme Disease Diagnostic Test Debuts at ADLM 2025

By LabMedica International staff writers
Posted on 31 Jul 2025

Lyme disease is the most common vector-borne illness in the U. More...

S., with an estimated 476,000 cases annually, though cases are likely underreported, according to the CDC. Though most prevalent in the Northeast, mid-Atlantic, and upper Midwest, cases have been reported in all 50 states and over 80 countries worldwide. Current Lyme disease diagnostics are complex. A new Lyme diagnostic test, utilizing artificial intelligence (AI) to enhance performance, has been introduced at this year’s ADLM Conference.

InBios International (Seattle, WA, USA) is developing the Lyme Detect Multiplex ELISA, an innovative array-based immunoassay in a traditional ELISA plate format that incorporates an automated software package to analyze, quantify, and, using machine learning interpretations, classify specimens. This novel approach is designed to significantly enhance workflow and acute-stage sensitivity for the diagnosis of Lyme disease.

InBios’ test advances beyond the standard two-tiered testing (STTT) and modified two-tiered testing (MTTT) for Lyme disease by combining IgG and IgM antibody detection in a single immunoassay. It simultaneously quantifies responses to a broad panel of B. burgdorferi antigens and utilizes machine-learning-guided analysis to determine the status of the clinical specimen, providing results in under two hours. Leveraging microarrays, machine learning, and automated interpretation, InBios’ assay significantly expands the amount and quality of data analyzed.

Pre-clinical and in-house performance testing compared InBios’ assay to the STTT and MTTT algorithms. Initial testing with blinded specimens indicated a statistically significant 30-40% sensitivity improvement for detecting early Lyme erythema migrans specimens when compared to STTT and a 15% improvement compared to MTTT, without compromising specificity. Minimal to no cross-reactivity was observed, even in problematic samples, including those positive for rheumatoid factor, syphilis, and fibromyalgia. The test debuted at ADLM 2025, where James Needham, PhD, InBios’ Director of Product Development, gave a talk titled “AI-Powered Lyme Diagnostics: The Future is Multiplexed” about the new diagnostic.

“InBios' new test simplifies the process, offering faster, more informative results compared to the traditional two-tier method,” said Needham. “It streamlines workflow by eliminating the need for sequential testing, which should result in faster turnaround times and reduced cost per patient.”

Related Links:
InBios International


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The novel approach could improve early cancer detection (Photo courtesy of AdobeStock)

Simple Blood Test Offers Non-Invasive Alternative for Early Colon Cancer Detection

Colorectal cancer remains one of the leading causes of cancer-related deaths, and early detection is critical for improving patient outcomes. Current methods, such as colonoscopy, are effective but invasive... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.